Fitzpatrick Jennifer 4

What Happened
Jennifer Fitzpatrick, Chief Legal Officer of Sionna Therapeutics (SION), exercised options for 10,250 shares and sold those 10,250 shares in the open market on March 5, 2026. The options were exercised at $6.11 per share (total exercise cost $62,628) and the shares were sold at a weighted average price of $33.86 per share for aggregate proceeds of $347,019. The sale was executed under a pre-existing Rule 10b5-1 trading plan.

Key Details

• Transaction date: March 5, 2026; Form 4 filed March 6, 2026 (timely filing).
• Option exercise: 10,250 shares acquired at $6.11 each (total $62,628).
• Open-market sale: 10,250 shares sold at a weighted average $33.86 (total $347,019). Reported sale prices ranged from $32.56 to $34.83.
• Additional derivative line: the filing also shows a related derivative conversion/disposition entry at $0.00 (recordkeeping treatment of the exercised derivative).
• Shares owned after the transaction: not specified in the information provided in the filing.
• Footnotes: sale was automatically executed under a Rule 10b5-1 plan adopted June 5, 2025 (F1); weighted-average price disclosure and range provided (F2); the option had partial vesting (25% vested June 3, 2025) with remaining shares vesting monthly over 36 months subject to continued service (F3).

Context
This was an option exercise followed by an immediate sale of the resulting shares (a common cashless/cash exercise pattern). The sale was pre-arranged under a 10b5-1 plan, which typically schedules trades in advance and helps avoid questions about timing or intent. The filing is factual and does not indicate the insider’s motive.